Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

(2019) Alok A. Khorana et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States

(2019) Ang Li et al.   THROMBOSIS RESEARCH

Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis

(2019) Nathan T. Connell et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta‐analysis

(2019) Ang Li et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis

(2018) Ang Li et al.   THROMBOSIS RESEARCH

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

(2018) Marc Carrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature

(2017) Yvonne M. Ende-Verhaar et al.   EUROPEAN RESPIRATORY JOURNAL

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer

(2017) Anja Katholing et al.   THROMBOSIS AND HAEMOSTASIS

Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol

(2016) Holger J Schünemann et al.   BMJ Open

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

(2014) D Papaioannou et al.   HEALTH TECHNOLOGY ASSESSMENT

Prophylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer

(2014) Jean M. Connors   NEW ENGLAND JOURNAL OF MEDICINE

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer

(2014) Alexander T. Cohen et al.   THROMBOSIS AND HAEMOSTASIS

Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial

(2013) Susan R Kahn et al.   LANCET

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

(2013) Don Husereau et al.   VALUE IN HEALTH

Estimating Quality of Life in Acute Venous Thrombosis

(2013) Kerstin Hogg et al.   JAMA Internal Medicine

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2011) Dorothy Romanus et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Excess Costs Associated with Patients with Pulmonary Arterial Hypertension in a US Privately Insured Population

(2011) Noam Y. Kirson et al.   Applied Health Economics and Health Policy

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

(2009) Giancarlo Agnelli et al.   LANCET ONCOLOGY

Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial

(2009) Desmond Curran et al.   QUALITY OF LIFE RESEARCH

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD

Cost‐effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome

(2008) Janice S. Kwon et al.   CANCER